InsidersTradesSigma
에이프릴바이오: directors' dealings · South Korea · DART (FSS)
DART:company-7406ddKR·DART (FSS)Mcap 1224.3Bn€Healthcare
Explore the full insider trade history of 에이프릴바이오, a listed equity based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Operating in the Healthcare sector, 에이프릴바이오 has published 4 insider filings. Market capitalisation: €1,224.3bn. The latest transaction was disclosed on 16 April 2026 — Purchase. Among the most active insiders: 서상준. All data is accessible without an account.
4
Insider Decl.
0
Thresholds
€276,769
3 ops.
Buy Volume
·
1 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
53700.00 €
Analyst consensus
1 analysts100000.00 €Target 100000.00 €(+86%)100000.00 €
Income statement
Revenue2.17 Bn€
Gross profit2.17 Bn€100% margin
Net income−9.73 Bn€-447.9% margin
Valuation
PER (forward)-56.2x
Beta1.51
Balance sheet & cash
Market cap1224.34 Bn€
Total debt498.0 M€
Free Cash Flow−3.63 Bn€
Debt / Equity1%
Profitability & ownership
ROE-10.4%
ROA-4.6%
% insiders19.4%
% institutions5.7%
Last declaration on 16 April 2026
Declarations4 total
4 of 4 declarations